Source:http://linkedlifedata.com/resource/pubmed/id/18004231
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2008-8-13
|
pubmed:abstractText |
Insulin-like growth factor (IGF) 1 has protective effects in liver failure. However, the effect of IGF-1 on inflammatory mediators such as proinflammatory cytokines and NO remains to be clarified. We hypothesized that IGF-1 inhibited the induction of these cytokines and iNOS, resulting in beneficial effect in the liver. Rats were treated with D-galactosamine (400 mg kg(-1)) and LPS (16 microg kg(-1)) (GalN/LPS) to induce acute liver failure. Insulin-like growth factor 1 (3.2 mg kg(-1)) was administered subcutaneously before GalN/LPS injection. Insulin-like growth factor 1 increased the survival rate in GalN/LPS-treated rats and prevented the increases of transaminases and total bilirubin in serum. Histopathological analysis revealed that IGF-1 decreased the incidence of hepatic apoptosis and neutrophil infiltration. Insulin-like growth factor 1 inhibited increases in TNF-alpha, IL-1 beta, and cytokine-induced neutrophil chemoattractant 1 caused by GalN/LPS in serum and liver and enhanced serum IL-10. Insulin-like growth factor 1 reduced the induction of iNOS mRNA and its protein in GalN/LPS-treated liver and resulted in a decrease in NO production. However, IGF-1 had no effect on the activation of nuclear factor-kappa B. Analysis of iNOS antisense-transcript revealed that IGF-1 accelerated the degradation of iNOS mRNA, rather than the inhibition of its synthesis. Insulin-like growth factor 1 may inhibit the induction of proinflammatory cytokines and iNOS through an nuclear factor-kappa B-independent pathway and have a novel therapeutic potential in the prevention of liver injury.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bilirubin,
http://linkedlifedata.com/resource/pubmed/chemical/Galactosamine,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Nos2 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Transaminases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1073-2322
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
740-7
|
pubmed:meshHeading |
pubmed-meshheading:18004231-Animals,
pubmed-meshheading:18004231-Bilirubin,
pubmed-meshheading:18004231-Enzyme Induction,
pubmed-meshheading:18004231-Galactosamine,
pubmed-meshheading:18004231-Humans,
pubmed-meshheading:18004231-Insulin-Like Growth Factor I,
pubmed-meshheading:18004231-Lipopolysaccharides,
pubmed-meshheading:18004231-Liver,
pubmed-meshheading:18004231-Liver Failure,
pubmed-meshheading:18004231-Male,
pubmed-meshheading:18004231-Nitric Oxide Synthase Type II,
pubmed-meshheading:18004231-RNA, Messenger,
pubmed-meshheading:18004231-RNA Stability,
pubmed-meshheading:18004231-Rats,
pubmed-meshheading:18004231-Rats, Sprague-Dawley,
pubmed-meshheading:18004231-Transaminases,
pubmed-meshheading:18004231-Tumor Necrosis Factor-alpha
|
pubmed:year |
2008
|
pubmed:articleTitle |
Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-alpha and iNOS induction in D-galactosamine and LPS-treated rats.
|
pubmed:affiliation |
The Department of Surgery, Kansai Medical University, Moriguchi, Osaka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|